Head to head
Veracyte vs Thermo Fisher Scientific
Side-by-side on the measures that matter, with a plain-English read. Full detail: VCYT · TMO
VCYT
Veracyte
25.13+0.36%
1-year price shape — -38% over the period
Quant Rating E · 11/100
vs
TMO
Thermo Fisher Scientific
669.54-2.79%
1-year price shape — +17% over the period
Quant Rating C · 61/100
1-year performance, rebased to 100
Thermo Fisher Scientific edges it on the scoreable measures. Thermo Fisher Scientific has the highest Quant Rating (61); Thermo Fisher Scientific has done best over the past year (+17%); Thermo Fisher Scientific pays the highest dividend yield.
| VCYT | TMO | |
|---|---|---|
| Snapshot | ||
| Sector | Diagnostics & Research | Diagnostics & Research |
| Last price | 25.13 | 669.54 |
| Change today | +0.36% | -2.79% |
| 1-year return | -38.5% | +17.2% |
| Market cap | $2.03B | $248.08B |
| 52-week range | 21.91 – 60.91 | 434.50 – 727.56 |
| Valuation | ||
| P/E (TTM) | 16.32 | 35.31 |
| P/E percentile, own 5-yr range | 66th | 89th |
| P/B | 1.41 | 4.53 |
| Dividend yield | 0.00% | 0.27% |
| Profitability & growth | ||
| EPS (TTM) | 0.82 | 17.74 |
| Net profit (TTM) | $66.17M | $6.57B |
| Revenue (TTM) | $581.78M | $47.35B |
| Provider revenue period date | 2026-09-29 | 2026-09-25 |
| Revenue growth (YoY) | +15.1% | +9.1% |
| Gross margin | 72.0% | 41.1% |
| Operating margin | 17.1% | 18.7% |
| Net margin | 21.8% | 14.9% |
| Free cash flow (TTM) | $161.95M | $7.60B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-25 |
| Ownership & sentiment | ||
| Institutional ownership | 118.5% | 94.1% |
| Insider activity (12mo) | 15 buy / 35 sell | 20 buy / 30 sell |
| Short interest (% of float) | 11.9% | 1.3% |
| Analyst consensus | 100% buy (7) | 88% buy / 12% hold (16) |
| Analyst price target | $48 (+91%) | $778 (+16%) |
| StockVane view | ||
| StockVane Quant Rating | E (11) | C (61) |
| Company | ||
| Employees | 755 | 125,000 |
| Founded | 2006 | 1956 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.